Executive Summary:
Bio-Path Holdings Inc. (BPTH) experienced a monumental surge in trading activity and price valuation following the announcement of successful clinical trial results. The charts present a compelling case for both bullish sentiment and caution due to the exceptional movements. In this advanced technical analysis, we'll dissect the current...
NASDAQ:BPTH Bio-Path Holdings Inc (% of Vol Shorted- Mar 11: 60.93%)
Sky High!!!
Target PTs 486 - 1,236 and higher
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology...
Try entering on 15 min if it breaks upwards from here, take part profit after a couple of hours, and rest of profit when closing below the 10 SMA.
˚. ✦.˳·˖✶ ⋆.˚. ✩₊˚.⋆
remember to use paper trade instead of real $$$$ friends
Bio-Path Holdings Inc (NASDAQ:BPTH) I've covered this low floater in the past, and it appears the stock is getting attention again. I've always felt this stock has potential to rally. From a technical standpoint, it needs to break through $6.20 to really get going. A break of that figure brings $7.80 into focus. Keep a close eye on this one the next few days.
I remember seeing this move live in real-time when it happened. It was amazing!
Thought of doing a study case of this pattern.
The chart is self-explanatory.
First, you wait for the first part of the pattern to happen ----> Huge gains + Huge Volume
Second, you watch it does the first pullback, and keep an eye on the HIGH.
Third, when the stock is making...
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology
Provides Expanded Protection to Seminal Patents Related to DNAbilize
The new patent builds on earlier patents granted that protect the platform technology for DNAbilize®, the Company’s novel RNAi nanoparticle drugs.
finance.yahoo.com
BPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact...
ANALYSTS UPGRADE WITH $28 TAGRGET
H.C. Wainwright analyst Yi Chen started Bio-Path Holdings with a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further,...
Stock picking has no certainties and often the greatest signals are from whispers among the investment community. Bi-Path Holdings has had quite a lot of good news recently that has brought it to the attention of many investors. Despite this we think that the price is gearing up for a significant move upwards, so we have alerts set on price and RSI spikes. This is...
